Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW
Authors:
Peter Rossing1,2; Morten Lindhardt2,3; Christian Klyver Tikkanen4; Jyothi Menon5; Juliette Cattin6; Barnaby Hunt6; Samuel JP Malkin6; Barrie Chubb5; Tina Damgaard4; Rikke Borg2,7